Drug Discovery Services Market Research Report – Forecast to 2027

Drug Discovery Services Market Research Report: By Drug Type (Small Molecule Drug, Biologics), by Type (DMPK, Pharmaceutical Services, Others), by Therapeutic Area (Oncology, Others), by Process, by Technology, and by End-User – Global Forecast Till 2027

ID: MRFR/Pharma/4414-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Drug discovery is the process of designing a new drug. The most common methods employed for drug discovery are molecular manipulation, random screening, drug metabolites, molecular designing, and serendipity. Drug discovery services are specifically designed to minimize the costs and timelines of drug discovery.


It is noted that the increasing demand for cancer treatment, technological advancements, and increasing healthcare expenditure are the key factors driving the drug discovery services market. According to the World Health Organization (WHO), cancer is one of the leading causes of mortality worldwide. The disease was responsible for 8.8 million deaths in 2015. The most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer. Cancer-causing infections are responsible for up to 25% cases of cancer in the low- and middle-income countries.


Various other factors such as the growing awareness about chronic diseases, increasing patient pool, unmet medical needs, patent expiration of blockbuster drugs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global drug discovery services market.


Despite these drivers, there are some setbacks associated with the drug discovery services market. The huge capital investment with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries may hinder the growth of the drug discovery services market to a considerable extent.


It is estimated that the drug discovery services market is expected to grow at a CAGR of 10.8% during the forecast period of 2017–2023.


Key Players


Some of the key players in the global drug discovery services market are Abbott Laboratories Inc., Advinus Therapeutics, Agilent Technologies Ubiquigent, Albany Molecular Research Inc. (AMRI), AstraZeneca PLC, Aurigene, Bayer AG, Charles River Laboratories International, ChemBridge Corporation, Covance, Eli Lilly and Company, Evotec, Domainex, F. Hoffmann-La Roche Ltd, GE Healthcare, GenScript, GlaxoSmithKline LLC, GVK Biosciences, Jubilant Biosys, Lonza, Merck, Pharmaceutical Product Development, LLC (PPD), Piramal Enterprises, Promega Corporation, Selcia Limited, Shimadzu Corp., SRI International, Syngene International Ltd., Thermo Fisher Scientific, Viva Biotech, WuXi AppTec, and others.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities


Segmentation


The global drug discovery services market is segmented by drug type, types of services, technology, therapeutic area, process, and end-user.


On the basis of drug type, the drug discovery services market is classified as small molecule drug and biologics drug.


On the basis of types of services, the drug discovery services market is classified as Drug Metabolism and Pharmacokinetics (DMPK) services, pharmaceutical services, medicinal chemistry, and biological services.


On the basis of technology, the drug discovery services market is classified as high throughput screening, biochips, pharmacogenomics and pharmacogenetics, combinatorial chemistry, nanotechnology, spectroscopy, metabolomics, and others.


On the basis of therapeutic area, the drug discovery services market is classified as oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and others.


On the basis of process, the drug discovery services market is classified as target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation.


On the basis of end-user, the drug discovery services market is segmented into hospitals and clinics, pharmaceutical companies, biotechnology companies, research institutes, and others.


Research Methodology


 Drug Discovery Services


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The Americas dominates the drug discovery services market owing to the increasing prevalence of chronic diseases and high healthcare expenditure. According to the data suggested by the Center for Disease Control and Prevention (CDC), around 92.1 million adults have at least one type of cardiovascular disease. It is also reported that around 15.1% of adults in the United States i.e. 36.5 million adults smoked cigarettes in 2015, which accounted for more than 480,000 deaths each year. Nearly 86% of the healthcare cost in the United States i.e. USD 2.7 trillion is spent for people with chronic and mental health conditions.


Europe holds the second position in the drug discovery services market. The financial support by the government towards research and development and patent expiration of various blockbuster drugs are expected to drive the European drug discovery services market. Various biologic drugs such as Genentech's Rituxan, Abbott & Eisai's Humira, and J&J's Remicade are likely to lose their patent protection in the coming years.


Asia Pacific is the fastest growing drug discovery services market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.


The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.


Global Drug Discovery Services Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa




Frequently Asked Questions (FAQ) :


Strict FDA Regulations are The Major Restraint On The Drug Discovery Services Market.

Drug Discovery Services Market is expected to exhibit a strong 10.8% CAGR over the forecast period from 2020 to 2027.

Growing pharmaceutical industry is the major driver for the drug discovery services market.

Americas dominate the global Drug Discovery Services Market.

Leading players in the Drug Discovery Services Market include GenScript, GSK, and AstraZeneca, among others

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Drug Discovery Services Market, by Drug Type

6.1 Introduction

6.2 Small Molecule Drug

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Biologics Drug

6.3.1 Market Estimates & Forecast, 2020–2027

Chapter 7. Global Drug Discovery Services Market, by Types of Services

7.1 Introduction

7.2 Drug Metabolism and Pharmacokinetics (DMPK) Services

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Pharmaceutical Services

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Medicinal Chemistry

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Biological Services

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Medication

7.6.1 Market Estimates & Forecast, 2020–2027

Chapter 8. Global Drug Discovery Services Market, by Technology

8.1 Introduction

8.2 High Throughput Screening

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Biochips

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Pharmacogenomics and Pharmacogenetics

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Combinatorial Chemistry

8.5.1 Market Estimates & Forecast, 2020–2027

8.6 Nanotechnology

8.6.1 Market Estimates & Forecast, 2020–2027

8.7 Spectroscopy

8.7.1 Market Estimates & Forecast, 2020–2027

8.8 Metabolomics

8.8.1 Market Estimates & Forecast, 2020–2027

8.9 Others

8.9.1 Market Estimates & Forecast, 2020–2027

Chapter 9. Global Drug Discovery Services Market, by Therapeutic Area

9.1 Introduction

9.2 Oncology

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Cardiovascular Diseases

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Respiratory Diseases

9.4.1 Market Estimates & Forecast, 2020–2027

9.5 Diabetes

9.5.1 Market Estimates & Forecast, 2020–2027

9.6 Others

9.6.1 Market Estimates & Forecast, 2020–2027

Chapter 10. Global Drug Discovery Services Market, by Process

10.1 Introduction

10.2 Target Selection

10.2.1 Market Estimates & Forecast, 2020–2027

10.3 Target Validation

10.3.1 Market Estimates & Forecast, 2020–2027

10.4 Hit-To-Lead Identification

10.4.1 Market Estimates & Forecast, 2020–2027

10.5 Lead Optimization

10.5.1 Market Estimates & Forecast, 2020–2027

10.6 Candidate Validation

10.6.1 Market Estimates & Forecast, 2020–2027

Chapter 11. Global Drug Discovery Services Market, by End-User

11.1 Introduction

11.2 Hospitals

11.2.1 Market Estimates & Forecast, 2020–2027

11.3 Clinics

11.3.1 Market Estimates & Forecast, 2020–2027

11.4 Diagnostic Centers

11.4.1 Market Estimates & Forecast, 2020–2027

11.5 Drug Stores

11.5.1 Market Estimates & Forecast, 2020–2027

11.6 Pharmacies

11.6.1 Market Estimates & Forecast, 2020–2027

11.7 Others

11.7.1 Market Estimates & Forecast, 2020–2027

Chapter 12. Global Drug Discovery Services Market, by Region

12.1 Introduction

12.2 Americas

12.2.1 North America

12.2.1.1 U.S.

12.2.1.1 Canada

12.2.2 South America

12.3 Europe

12.3.1 Western Europe

12.3.1.1 Germany

12.3.1.2 France

12.3.1.3 Italy

12.3.1.4 Spain

12.3.1.5 U.K.

12.3.1.6 Rest of Western Europe

12.3.2 Eastern Europe

12.4 Asia Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 Republic of Korea

12.4.6 Rest of Asia Pacific

12.5 The Middle East & Africa

12.5.1 United Arab Emirates

12.5.2 Saudi Arabia

12.5.3 Oman

12.5.4 Kuwait

12.5.5 Qatar

12.5.6 Rest of the Middle East & Africa

Chapter 13 Company Landscape

13.1 Introduction

13.2 Market Share Analysis

13.3 Key Development & Strategies

13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 Eli Lilly and Company’s

14.1.1 Company Overview

14.1.2 Types Overview

14.1.3 Financials

14.1.4 SWOT Analysis

14.2 Thermo Fisher Scientific

14.2.1 Company Overview

14.2.2 Types Overview

14.2.3 Financial Overview

14.2.4 Key Developments

14.2.5 SWOT Analysis

14.3 GVK Biosciences

14.3.1 Company Overview

14.3.2 Types Overview

14.3.3 Financial Overview

14.3.4 Key Development

14.3.5 SWOT Analysis

14.4 Merck

14.4.1 Company Overview

14.4.2 Types/Business Segment Overview

14.4.3 Financial Overview

14.4.4 Key Development

14.4.5 SWOT Analysis

14.5 GLAXOSMITHKLINE

14.5.1 Company Overview

14.5.2 Types Overview

14.5.3 Financial overview

14.5.4 Key Developments

14.6 Albany Molecular Research Inc. (AMRI)

14.6.1 Company Overview

14.6.2 Types Overview

14.6.3 Financial Overview

14.6.4 Key Developments

14.7 CHARLES RIVER LABORATORIES INTERNATIONAL

14.7.1 Overview

14.7.2 Types Overview

14.7.3 Financials

14.7.4 Key Developments

14.7.5 SWOT Analysis

14.8 Others

Chapter 15 MRFR Conclusion

15.1 Key Findings

15.1.1 From CEO’s View Point

15.1.2 Unmet Needs of the Market

15.2 Key Companies to Watch

15.3 Prediction of the Drug Discovery Services Industry

Chapter 16 Appendix

LIST OF TABLES

Table 1 Drug Discovery Services Industry Synopsis, 2020–2027

Table 2 Drug Discovery Services Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Drug Discovery Services Market, by Region, 2020–2027, (USD Million)

Table 4 Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 5 Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 6 Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 7 Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 8 Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 9 Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 10 North America Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 11 North America Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 12 North America Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 13 North America Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 14 North America Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 15 North America Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 16 U.S. Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 17 U.S. Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 18 U.S. Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 19 U.S. Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 20 U.S. Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 21 U.S. Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 22 Canada Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 23 Canada Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 24 Canada Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 25 Canada Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 26 Canada Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 27 Canada Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 28 South America Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 29 South America Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 30 South America Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 31 South America Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 32 South America Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 33 South America Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 34 Europe Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 35 Europe Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 36 Europe Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 37 Europe Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 38 Europe Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 39 Europe Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 40 Western Europe Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 41 Western Europe Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 42 Western Europe Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 43 Western Europe Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 44 Western Europe Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 45 Western Europe Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 46 Eastern Europe Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 47 Eastern Europe Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 48 Eastern Europe Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 49 Eastern Europe Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 50 Eastern Europe Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 51 Eastern Europe Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 52 Asia Pacific Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 53 Asia Pacific Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 54 Asia Pacific Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 55 Asia Pacific Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 56 Asia Pacific Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 57 Asia Pacific Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

Table 58 The Middle East & Africa Drug Discovery Services Market, by Drug Type, 2020–2027, (USD Million)

Table 59 The Middle East & Africa Drug Discovery Services Market, by Types of Services, 2020–2027, (USD Million)

Table 60 The Middle East & Africa Drug Discovery Services Market, by Technology, 2020–2027, (USD Million)

Table 61 The Middle East & Africa Drug Discovery Services Market, by Therapeutic Area, 2020–2027, (USD Million)

Table 62 The Middle East & Africa Drug Discovery Services Market, by Process, 2020–2027, (USD Million)

Table 63 The Middle East & Africa Drug Discovery Services Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Drug Discovery Services Market

Figure 3 Segmentation Market Dynamics for Drug Discovery Services Market

Figure 4 Global Drug Discovery Services Market Share, by Drug Type 2020

Figure 5 Global Drug Discovery Services Market Share, by Types of Services 2020

Figure 6 Global Drug Discovery Services Market Share, by Technology 2020

Figure 7 Global Drug Discovery Services Market Share, by Therapeutic Area 2020

Figure 8 Global Drug Discovery Services Market Share, by Process 2020

Figure 9 Global Drug Discovery Services Market Share, by End-User, 2020

Figure 10 Global Drug Discovery Services Market Share, by Region, 2020

Figure 11 North America Drug Discovery Services Market Share, by Country, 2020

Figure 12 Europe Drug Discovery Services Market Share, by Country, 2020

Figure 13 Asia Pacific Drug Discovery Services Market Share, by Country, 2020

Figure 14 Middle East & Africa Drug Discovery Services Market Share, by Country, 2020

Figure 15 Global Drug Discovery Services market: Company Share Analysis, 2020 (%)

Figure 16 Eli Lilly and Company’s: Key Financials

Figure 17 Eli Lilly and Company’s: Segmental Revenue

Figure 18 Eli Lilly and Company’s: Geographical Revenue

Figure 19 Thermo Fisher Scientific: Key Financials

Figure 20 Thermo Fisher Scientific: Segmental Revenue

Figure 21 Thermo Fisher Scientific: Geographical Revenue

Figure 22 GVK Biosciences: Key Financials

Figure 23 GVK Biosciences: Segmental Revenue

Figure 24 GVK Biosciences: Geographical Revenue

Figure 25 Merck: Key Financials

Figure 26 Merck: Segmental Revenue

Figure 27 Merck: Geographical Revenue

Figure 28 GLAXOSMITHKLINE: Key Financials

Figure 29 GLAXOSMITHKLINE: Segmental Revenue

Figure 30 GLAXOSMITHKLINE Geographical Revenue

Figure 31 Albany Molecular Research Inc. (AMRI): Key Financials

Figure 32 Albany Molecular Research Inc. (AMRI): Segmental Revenue

Figure 33 Albany Molecular Research Inc. (AMRI): Geographical Revenue

Figure 34 CHARLES RIVER LABORATORIES INTERNATIONAL: Key Financials

Figure 35 CHARLES RIVER LABORATORIES INTERNATIONAL: Segmental Revenue

Figure 36 CHARLES RIVER LABORATORIES INTERNATIONAL: Geographical Revenue